We are monitoring the impact of COVID-19 on Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 157
Share on
Share on

Global Cancer Monoclonal Antibodies Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Application, Type, Conjugate Cancer Therapies & Region – Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 157
Pages: 173

Cancer Monoclonal Antibodies Market Size (2021 to 2026)

The size of the global cancer monoclonal antibodies market is forecasted to be worth USD 78.55 billion by 2026 from USD 45.97 billion in 2021, registering a CAGR of 11.31% between 2021 to 2026.

Cancer is a severe disease-causing million of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell into a tumor cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest in monoclonal antibodies. While the drugs are used to treat cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells and cancerous cells. Therefore, it prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.

Monoclonal Antibodies (mAbs) are mono-specific antibody bodies comprising identical immune cells clones of a single parent cell and directed to specific cellular targets. Thus, Monoclonal Antibodies are highly customizable due to their particular nature and can play a crucial role in eliminating cancerous cells while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.

Monoclonal Antibodies could offer less toxic and efficient therapeutic alternatives to patients emerging in recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory, and especially cancer.

MARKET DRIVERS:

A few of the significant factors driving the global cancer monoclonal antibodies market are the increasing prevalence of cancer, increasing investment in R&D of genomic studies, and increasing progress and preference towards the specificity of monoclonal antibodies to attack cancer.

According to the WHO, cancer is the second leading cause of death globally, registering for an estimated 9.9 million deaths, or 1 in 6 deaths, in 2019. Cancer-associated with prostate, colorectal & liver is the most common cancer in men, while cancer associated with colorectal, lung, cervical & thyroid cancer are most commonly affected by women. Therefore, the increase in data should inform any national cancer policy, leading to an increase in the percentage of people choosing cancer treatment. In the health sector, cancer is one of the biggest concerns. Therefore, the increased use of monoclonal antibodies for cancer treatment is boosting this market.

The dramatic increase in cancer patients has led many pharmaceutical players to invest in the monoclonal antibodies market. Increasing investment in research and development of genomic studies, technological advancements in genetic sequencing and target gene selection, and a specificity of monoclonal antibodies to target only the cancer cells with no side effects are some of the market's driving forces. The increased prevalence of cancer is the key driver of the monoclonal antibodies market. It is expected to grow lucratively in the next five years with health products in the pipeline.

There is a rapid increase in research and the development of genomic studies due to the growing demand. This has led to a rapid increase in the growth of the Monoclonal Cancer Antibodies market. In addition, it is also believed that the increase in the prevalence of breast cancer will promote the growth of the Monoclonal Cancer Antibodies market.

MARKET RESTRAINTS:

However, following regulatory guidelines for cancer-related monoclonal antibodies is a very rigorous process in most parts of the world. The guidelines provide a complete description of the manufacturing processes, including quality, good manufacturing practices, process validation, and potential for degradation, and the need for stability studies. Therefore, globally, there is a strict regulatory scenario like the US FDA, European Medicines Agency (EMA), and Korean FDA. Cancer antibodies also face similar restrictions in gaining approval for monoclonal antibodies in the market. As this is a long process, it is considered one of the main hurdles for this market.

The growth of the cancer monoclonal antibodies market is a long period of research and development before clinical trials, the increase in mAbs failures in clinical trials, and the high cost of the products defying the market's growth rate.

Impact of COVID-19 on the global cancer monoclonal antibodies market:

The World Health Organization (WHO) declared the COVID 19 pandemic a public health emergency issue affecting millions of people and has spread to every corner of the world. The pandemic has affected all sectors, including the medical field. During the COVID 19 outrage, the pharma industry is more bothered about developing the COVID vaccine. As a result, cancer monoclonal antibodies' research and development activities have taken a drop, even though the demand for cancer monoclonal antibodies is stable and high before the pandemic. During the pandemic lockdown, there has been a slight decline in the cancer monoclonal antibodies. However, the market position is forecasted to fall in its place by the end of 2021.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Application, Type, Conjugate Cancer Therapies, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

AmgenGenmabGlaxoSmithKlineBristol Myers SquibbRoche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals.

 

This research report on the global cancer monoclonal antibodies market has been segmented and sub-segmented based on application, type, conjugate cancer therapies, and region.

Cancer Monoclonal Antibodies Market - By Application:

  • Liver
  • Breast
  • Brain
  • Blood
  • Hodgkins and Non-Hodgkins lymphoma           
  • Colorectal
  • Leukemia
  • Others

Based on the application, the breast cancer application segment held the highest share in the cancer monoclonal antibodies market in 2019. Growing exposure to harmful radiation, insufficient physical exercise, and expanding adoption of unhealthy lifestyles mobilize the market growth. In addition, large companies' growth in investments, increasing government initiatives, and rising female population push the market forward.

Cancer Monoclonal Antibodies Market - By Type:

  • Murine Antibodies
  • Chimeric and Humanised Antibodies
  • Fully Humanized Antibodies

Based on type, the murine antibodies account for the lion's share in the cancer monoclonal antibodies type during the forecast period. The murine antibodies play a significant role in advancements of present-day antibody production procedures and developing the potential usage of immunoglobins for various applications propelling the market growth. 

The fully humanized antibodies segment is the quickest growing, with a CAGR rate during the forecasting framework. In addition, the integration of advanced technologies like yeast or phase display showcases their market growth. 

Cancer Monoclonal Antibodies Market - By Conjugate Cancer Therapies:

  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines
  • Others

The radioimmunotherapy segment is forecasted to play a dominating role in the cancer monoclonal antibodies market during the forecast period due to the increasing number of cancer patients with the growing number of hospitals and diagnostic centers.

Cancer Monoclonal Antibodies Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America dominated the global cancer monoclonal antibodies market due to a well-maintained healthcare infrastructure, increased government expenditure for infection control and management, and the rising commonness of life-style related diseases. In addition, the North American area is regarded to show the same growth due to its rise in cancer research and technology development.

Europe is anticipated to show an essential growth in the market due to increased autoimmune diseases' commonness, increasing the cancer population, and rising funding in research and development in the monoclonal antibodies market.

The Asia-Pacific market is regarded to increase significantly due to increased spending capacity and the growing knowledge among the patients.

KEY MARKET PLAYERS:

The highly customizable nature of the monoclonal antibodies attracts various organizations, research institutes, and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals.

RECENT MARKET DEVELOPMENTS:

  • In 2018, Pfizer Inc. declared the US FDA approval of ZIRABEV (bevacizumab-bvzr). It is a biosimilar to Avastin (bevacizumab), which is indicated to treat five types of cancer, including locally advanced, relapsed or metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer, non-metastatic renal cell carcinoma resectable (CCR), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer.
  • This is the second oncology monoclonal antibody biosimilar to gain FDA approval, after TRAZIMERA (trastuzumab-qyyp) in March 2019. This new biosimilar may help increase access to impactful therapies, thereby accelerating competition in the market. As a result, it can potentially reduce costs and help meet the various demands of cancer patients.
  • In 2016, ImmunoGen Inc agreed with Merck to evaluate mirvetuximab soravtansine to treat patients with FRα-positive ovarian cancer.
  • In 2020, Merck launched the biosimilar trastuzumab, a monoclonal antibody used to treat certain breast cancers.
  1. Introduction

                1.1 Market Definition                                                                    

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                          

                1.4 General Study Assumptions                                                                

  1. Research Methodology

                2.1 Introduction                                                                               

                2.2 Research Phases                                                                      

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                                                                         

                2.4 Study Timeline                                                                          

  1. Overview

                3.1 Executive Summary                                                                

                3.2 Key Inferences                                                                         

                3.3 New Developments                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                          

                4.2 Market Restraints                                                                    

                4.3 Key Challenges                                                                         

                4.4 Current Opportunities in the Market                                                                              

  1. Market Segmentation

                5.1 By Application                                                                           

                                5.1.1 Liver                                                           

                                5.1.2 Breast                                                       

                                5.1.3 Brain                                                          

                                5.1.4 Blood                                                         

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma                                                    

                                5.1.6 Colorectal                                                

                                5.1.7 Leukaemia                                                              

                                5.1.8 Others                                                      

                5.2 By Type                                                                        

                                5.2.1 Murine Antibodies                                                              

                                5.2.2 Chimeric and Humanised Antibodies                                                           

                                5.2.3 Fully Humanized Antibodies                                                            

                5.3 Conjugate Cancer Therapies                                                                               

                                5.3.1 Immunoliposome                                                

                                5.3.2 Radioimmunotherapy                                                        

                                5.3.3 ADEPT                                                       

                                5.3.4 Immunocytokines                                                

                                5.3.5 Others                                                      

  1. Geographical Analysis

                6.1 North America                                                                          

                                6.1.1 Introduction                                                           

                                6.1.2 United States                                                         

                                6.1.3 Canada                                                     

                6.2 Europe                                                                         

                                6.2.1 Introduction                                                           

                                6.2.2 U.K                                                             

                                6.2.3 Spain                                                         

                                6.2.4 Germany                                                 

                                6.2.5 Italy                                                            

                                6.2.6 France                                                       

                6.3 Asia-Pacific                                                                 

                                6.3.1 Introduction                                                           

                                6.3.2 China                                                         

                                6.3.3 India                                                          

                                6.3.4 Japan                                                         

                                6.3.5 South Korea                                                           

                6.4 Latin America                                                                             

                                6.4.1 Introduction                                                           

                                6.4.2 Brazil                                                          

                                6.4.3 Mexico                                                     

                                6.4.4 Rest of Latin America                                                          

                6.5 Middle East & Africa                                                                               

                                6.5.1 Introduction                                                           

                                6.5.2 Middle-East                                                            

                                6.5.3 Africa                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                         

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

  1. Market Leaders' Analysis

                8.1 Roche                                                           

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Strategic Evaluation and Operations                                                            

                                8.1.4 Financial analysis                                                  

                                8.1.5 Legal issues                                                             

                                8.1.6 Recent Developments                                                       

                                8.1.7 SWOT analysis                                                       

                                8.1.8 Analyst View                                                          

                8.2 Amgen                                                         

                8.3 Genmab                                                      

                8.4 Glaxosmithkline                                                       

                8.5 Bristol Meyer Squibb                                                              

                8.6 Eli Lilly                                                           

                8.7 Immunogen                                                               

                8.8 Novartis                                                       

                8.9 Seattle Genetics                                                       

                8.10 Spectrum Pharmaceuticals                                                

  1. Competitive Landscape

                9.1 Market share analysis                                                                            

                9.2 Merger and Acquisition Analysis                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                         

                9.4 New Product Launches                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                     

                10.2 Investment Opportunities                                                                 

     Appendix                                                                                           

  1. List of Tables
  2. List of Figures
  • Global, regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  3. Global Liver Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Breast Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Brain Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Blood Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  12. Global Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  15. Global Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  16. Global Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  18. Global ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  19. Global Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  20. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  23. North America Liver Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Breast Market, By Region, From 2021 to 2026 (USD Million)
  25. North America Brain Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Blood Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  30. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  32. North America Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  34. North America Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  35. North America Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  36. North America Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  37. North America Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  38. North America ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  39. North America Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  40. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  41. Europe Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  42. Europe Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  43. Europe Liver Market, By Region, From 2021 to 2026 (USD Million)
  44. Europe Breast Market, By Region, From 2021 to 2026 (USD Million)
  45. Europe Brain Market, By Region, From 2021 to 2026 (USD Million)
  46. Europe Blood Market, By Region, From 2021 to 2026 (USD Million)
  47. Europe Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  48. Europe Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  49. Europe Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  50. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  51. Europe Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  52. Europe Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  53. Europe Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  54. Europe Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  55. Europe Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  56. Europe Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  57. Europe Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  58. Europe ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  59. Europe Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  60. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  61. Asia-Pacific Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  62. Asia-Pacific Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  63. Asia-Pacific Liver Market, By Region, From 2021 to 2026 (USD Million)
  64. Asia-Pacific Breast Market, By Region, From 2021 to 2026 (USD Million)
  65. Asia-Pacific Brain Market, By Region, From 2021 to 2026 (USD Million)
  66. Asia-Pacific Blood Market, By Region, From 2021 to 2026 (USD Million)
  67. Asia-Pacific Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  68. Asia-Pacific Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  69. Asia-Pacific Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  70. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  71. Asia-Pacific Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  72. Asia-Pacific Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  73. Asia-Pacific Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  74. Asia-Pacific Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  75. Asia-Pacific Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  76. Asia-Pacific Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  77. Asia-Pacific Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  78. Asia-Pacific ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  79. Asia-Pacific Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  80. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  81. Latin America Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  82. Latin America Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  83. Latin America Liver Market, By Region, From 2021 to 2026 (USD Million)
  84. Latin America Breast Market, By Region, From 2021 to 2026 (USD Million)
  85. Latin America Brain Market, By Region, From 2021 to 2026 (USD Million)
  86. Latin America Blood Market, By Region, From 2021 to 2026 (USD Million)
  87. Latin America Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  88. Latin America Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  89. Latin America Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  90. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  91. Latin America Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  92. Latin America Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  93. Latin America Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  94. Latin America Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  95. Latin America Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  96. Latin America Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  97. Latin America Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  98. Latin America ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  99. Latin America Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  100. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  101. Middle East & Africa Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  102. Middle East & Africa Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  103. Middle East & Africa Liver Market, By Region, From 2021 to 2026 (USD Million)
  104. Middle East & Africa Breast Market, By Region, From 2021 to 2026 (USD Million)
  105. Middle East & Africa Brain Market, By Region, From 2021 to 2026 (USD Million)
  106. Middle East & Africa Blood Market, By Region, From 2021 to 2026 (USD Million)
  107. Middle East & Africa Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  108. Middle East & Africa Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  109. Middle East & Africa Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  110. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  111. Middle East & Africa Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  112. Middle East & Africa Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  113. Middle East & Africa Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  114. Middle East & Africa Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  115. Middle East & Africa Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  116. Middle East & Africa Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  117. Middle East & Africa Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  118. Middle East & Africa ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  119. Middle East & Africa Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  120. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample